Stock Yards Bank & Trust Co. Has $51.42 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Posted by on Apr 27th, 2023

Stock Yards Bank & Trust Co. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 291,101 shares of the company’s stock after purchasing an additional 2,318 shares during the quarter. Johnson & Johnson comprises 2.0% of Stock Yards Bank & Trust Co.’s holdings, making the stock its 10th largest holding. Stock Yards Bank & Trust Co.’s holdings in Johnson & Johnson were worth $51,423,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Glassy Mountain Advisors Inc. purchased a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $35,000. Retirement Financial Solutions LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $40,000. TD Capital Management LLC purchased a new position in Johnson & Johnson in the third quarter worth $48,000. VitalStone Financial LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $52,000. Finally, Iron Horse Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 112.8% during the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after purchasing an additional 159 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on JNJ shares. Atlantic Securities reduced their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. Piper Sandler cut their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. UBS Group assumed coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. Finally, StockNews.com began coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They set a “strong-buy” rating for the company. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

Johnson & Johnson Stock Down 1.5 %

Shares of JNJ opened at $162.62 on Thursday. The stock’s 50-day moving average price is $157.64 and its 200-day moving average price is $167.00. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $423.51 billion, a price-to-earnings ratio of 34.02, a PEG ratio of 2.79 and a beta of 0.53. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $184.82.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The business had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. During the same quarter last year, the company earned $2.67 EPS. The business’s revenue was up 5.6% on a year-over-year basis. On average, sell-side analysts predict that Johnson & Johnson will post 10.67 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.93%. Johnson & Johnson’s dividend payout ratio (DPR) is 94.56%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.